101
|
Stockmann S, Kuhn J, Zirngibl A, Mansmann U. Kommunale Gesundheitsberichterstattung in Deutschland: eine empirische Erhebung. DAS GESUNDHEITSWESEN 2008; 70:679-83. [DOI: 10.1055/s-0028-1100402] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
102
|
Nieves F, Cooper J, Mangold G, Kuhn J, Takimoto C, Tolcher A, Wick M. 72 POSTER Preclinical evaluation of the tyrosine kinase inhibitor erlotinib: Bioanalytical method development and pharmacokinetic analysis and in vivo evaluation and comparison in a panel of human EGFR wildtype and mutant tumor xenograft models. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)72004-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
103
|
Xu Y, Kolesar JM, Schaaf LJ, Drengler R, Duan W, Otterson G, Shapiro C, Kuhn J, Villalona-Calero MA. Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies. Cancer Chemother Pharmacol 2008; 63:1073-82. [PMID: 18795290 DOI: 10.1007/s00280-008-0826-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2008] [Accepted: 08/16/2008] [Indexed: 01/04/2023]
Abstract
PURPOSE Based on the preclinical evidence of topoisomerase I (Topo-1) upregulation by mitomycin C(MMC) and decreased NF-kappaB activation by celecoxib, we evaluated combinations of irinotecan/MMC and irinotecan/MMC/celecoxib in patients with advanced solid malignancies. PATIENTS-METHODS Initially, patients received MMC on day 1 and irinotecan on days 2, 8, 15 and 22, every 6 weeks. MMC dose was fixed at 6 mg/m(2) and cumulative doses of >36 mg/m(2) were not permitted. Irinotecan was escalated in 25 mg/m(2) increments. Due to late-onset diarrhea, the schedule was subsequently shortened to 4 weeks, omitting irinotecan on days 15 and 22. In the second part of the study, celecoxib 400 mg orally twice daily was added to irinotecan/MMC regimen. Potential pharmacokinetic interactions and Topo-1 and DT-diaphorase (NQ01) gene expressions in peripheral-mononuclear cells were evaluated. RESULTS Forty-five patients were enrolled. Irinotecan 125 mg/m(2) on days 2 and 8 in combination with MMC 6 mg/m(2) on day 1 every 4 weeks is recommended for future studies; myelosuppression and diarrhea are dose-limiting. The addition of celecoxib resulted in unacceptable toxicities despite reductions on irinotecan's dose. No relevant pharmacokinetic interactions occurred between irinotecan and MMC, and mean increases in Topo-1, were observed. Sixteen of 36 patients evaluable for response-assessment had discernable anti-tumor activity, including 1 complete, 4 partial, 10 minor and 1 tumor marker response. Four patients had prolonged (>4 months) disease-stability (stable disease, not included in CR or PR). Patients experiencing complete and partial responses had higher increments in Topo-1 expression. CONCLUSIONS Modulation of irinotecan by MMC is feasible, devoid of pharmacological interactions and active in solid malignancies. The lack of improvement in therapeutic index does not support the addition of celecoxib.
Collapse
|
104
|
Kuhn J, Bolte G. Das Thema „Rauchen und Nichtrauchen“ in der bayerischen Gesundheitsberichterstattung. DAS GESUNDHEITSWESEN 2008. [DOI: 10.1055/s-0028-1086309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
105
|
Stockmann S, Kuhn J, Zirngibl A, Mansmann U. Kommunale Gesundheitsberichterstattung in Deutschland – eine empirische Erhebung. DAS GESUNDHEITSWESEN 2008. [DOI: 10.1055/s-0028-1086227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
106
|
Bauer R, Pohl S, Klosterkötter J, Kuhn J. Abhängigkeitserkrankungen im Kontext der Tiefen Hirnstimulation – eine literaturgestützte systematische Auswertung. FORTSCHRITTE DER NEUROLOGIE-PSYCHIATRIE 2008; 76:396-401. [DOI: 10.1055/s-2008-1038217] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
107
|
Dror Y, Kuhn J, Avrahami R, Zussman E. Encapsulation of Enzymes in Biodegradable Tubular Structures. Macromolecules 2008. [DOI: 10.1021/ma071599r] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
108
|
Grabinski JL, Chisholm G, Smith LS, Drengler RL, Kalter S, Rodriguez G, Garner A, Cooper J, Pollock B, Kuhn J. ER alpha genotypes and breast cancer recurrence. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.501] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
109
|
Girod FX, Niyazov RA, Avakian H, Ball J, Bedlinskiy I, Burkert VD, De Masi R, Elouadrhiri L, Garçon M, Guidal M, Jo HS, Joo K, Kubarovsky V, Kuleshov SV, MacCormick M, Niccolai S, Pogorelko O, Sabatié F, Stepanyan S, Stoler P, Ungaro M, Zhao B, Amaryan MJ, Ambrozewicz P, Anghinolfi M, Asryan G, Bagdasaryan H, Baillie N, Ball JP, Baltzell NA, Batourine V, Battaglieri M, Bellis M, Benmouna N, Berman BL, Biselli AS, Blaszczyk L, Bouchigny S, Boiarinov S, Bradford R, Branford D, Briscoe WJ, Brooks WK, Bültmann S, Butuceanu C, Calarco JR, Careccia SL, Carman DS, Casey L, Chen S, Cheng L, Cole PL, Collins P, Coltharp P, Crabb D, Crede V, Dashyan N, De Sanctis E, De Vita R, Degtyarenko PV, Deur A, Dharmawardane KV, Dickson R, Djalali C, Dodge GE, Donnelly J, Doughty D, Dugger M, Dzyubak OP, Egiyan H, Egiyan KS, El Fassi L, Eugenio P, Fedotov G, Feldman G, Funsten H, Gavalian G, Gilfoyle GP, Giovanetti KL, Goetz JT, Gonenc A, Gothe RW, Griffioen KA, Guler N, Guo L, Gyurjyan V, Hafidi K, Hakobyan H, Hanretty C, Hersman FW, Hicks K, Hleiqawi I, Holtrop M, Hyde CE, Ilieva Y, Ireland DG, Ishkhanov BS, Isupov EL, Ito MM, Jenkins D, Johnstone JR, Juengst HG, Kalantarians N, Kellie JD, Khandaker M, Kim W, Klein A, Klein FJ, Klimenko AV, Kossov M, Krahn Z, Kramer LH, Kuhn J, Kuhn SE, Lachniet J, Laget JM, Langheinrich J, Lawrence D, Lee T, Livingston K, Lu HY, Markov N, Mattione P, Mazouz M, McKinnon B, Mecking BA, Mestayer MD, Meyer CA, Mibe T, Michel B, Mikhailov K, Mirazita M, Miskimen R, Mokeev V, Moriya K, Morrow SA, Moteabbed M, Munevar E, Mutchler GS, Nadel-Turonski P, Nasseripour R, Niculescu G, Niculescu I, Niczyporuk BB, Niroula MR, Nozar M, Osipenko M, Ostrovidov AI, Park K, Pasyuk E, Paterson C, Anefalos Pereira S, Pierce J, Pivnyuk N, Pocanic D, Pozdniakov S, Price JW, Procureur S, Prok Y, Protopopescu D, Raue BA, Ricco G, Ripani M, Ritchie BG, Rosner G, Rossi P, Salamanca J, Salgado C, Santoro JP, Sapunenko V, Schumacher RA, Serov VS, Sharabian YG, Sharov D, Shvedunov NV, Smith ES, Smith LC, Sober DI, Sokhan D, Stavinsky A, Stepanyan SS, Stokes BE, Strakovsky II, Strauch S, Taiuti M, Tedeschi DJ, Tkabladze A, Tkachenko S, Tur C, Vineyard MF, Vlassov AV, Voutier E, Watts DP, Weinstein LB, Weygand DP, Williams M, Wolin E, Wood MH, Yegneswaran A, Zana L, Zhang J, Zhao ZW. Measurement of deeply virtual compton scattering beam-spin asymmetries. PHYSICAL REVIEW LETTERS 2008; 100:162002. [PMID: 18518188 DOI: 10.1103/physrevlett.100.162002] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/06/2007] [Indexed: 05/26/2023]
Abstract
The beam-spin asymmetries in the hard exclusive electroproduction of photons on the proton (e p-->epgamma) were measured over a wide kinematic range and with high statistical accuracy. These asymmetries result from the interference of the Bethe-Heitler process and of deeply virtual Compton scattering. Over the whole kinematic range (x(B) from 0.11 to 0.58, Q2 from 1 to 4.8 GeV2, -t from 0.09 to 1.8 GeV2), the azimuthal dependence of the asymmetries is compatible with expectations from leading-twist dominance, A approximately a sinphi/(1+c cosphi). This extensive set of data can thus be used to constrain significantly the generalized parton distributions of the nucleon in the valence quark sector.
Collapse
|
110
|
Huff W, Kuhn J, Lenartz D, Lee SH, Klosterkötter J, Sturm V. Deep brain stimulation in the Nucleus accumbens – outcomes after one year stimulation in patients with treatment resistant obsessive compulsive disorder. KLIN NEUROPHYSIOL 2008. [DOI: 10.1055/s-2008-1072835] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
111
|
Kuhn J, Lenartz D, Heuckmann J, Huff W, Klosterkötter J, Sturm V. Deep brain stimulation of different anatomic structures in therapeutically refractory Tourette-syndrome. KLIN NEUROPHYSIOL 2008. [DOI: 10.1055/s-2008-1072992] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
112
|
Stockmann S, Kuhn J, Zirngibl A, Mansmann U. Kommunale Gesundheitsberichterstattung in Deutschland – eine empirische Erhebung. DAS GESUNDHEITSWESEN 2008. [DOI: 10.1055/s-2008-1076578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
113
|
Kuhn J, Morlock G, Helmert U. Gesundheitsberichterstattung über Adipositas: Zum öffentlichen Umgang mit Daten. DAS GESUNDHEITSWESEN 2008. [DOI: 10.1055/s-2008-1076514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
114
|
Ireland DG, McKinnon B, Protopopescu D, Ambrozewicz P, Anghinolfi M, Asryan G, Avakian H, Bagdasaryan H, Baillie N, Ball JP, Baltzell NA, Batourine V, Battaglieri M, Bedlinskiy I, Bellis M, Benmouna N, Berman BL, Biselli AS, Blaszczyk L, Bouchigny S, Boiarinov S, Bradford R, Branford D, Briscoe WJ, Brooks WK, Burkert VD, Butuceanu C, Calarco JR, Careccia SL, Carman DS, Casey L, Chen S, Cheng L, Cole PL, Collins P, Coltharp P, Crabb D, Crede V, Dashyan N, De Masi R, De Vita R, De Sanctis E, Degtyarenko PV, Deur A, Dickson R, Djalali C, Dodge GE, Donnelly J, Doughty D, Dugger M, Dzyubak OP, Egiyan KS, El Fassi L, Elouadrhiri L, Eugenio P, Fedotov G, Feldman G, Fradi A, Funsten H, Garçon M, Gavalian G, Gevorgyan N, Gilfoyle GP, Giovanetti KL, Girod FX, Goetz JT, Gohn W, Gonenc A, Gothe RW, Griffioen KA, Guidal M, Guler N, Guo L, Gyurjyan V, Hafidi K, Hakobyan H, Hanretty C, Hassall N, Hersman FW, Hleiqawi I, Holtrop M, Hyde-Wright CE, Ilieva Y, Ishkhanov BS, Isupov EL, Jenkins D, Jo HS, Johnstone JR, Joo K, Juengst HG, Kalantarians N, Kellie JD, Khandaker M, Kim W, Klein A, Klein FJ, Kossov M, Krahn Z, Kramer LH, Kubarovsky V, Kuhn J, Kuleshov SV, Kuznetsov V, Lachniet J, Laget JM, Langheinrich J, Lawrence D, Livingston K, Lu HY, Maccormick M, Markov N, Mattione P, Mecking BA, Mestayer MD, Meyer CA, Mibe T, Mikhailov K, Mirazita M, Miskimen R, Mokeev V, Moreno B, Moriya K, Morrow SA, Moteabbed M, Munevar E, Mutchler GS, Nadel-Turonski P, Nasseripour R, Niccolai S, Niculescu G, Niculescu I, Niczyporuk BB, Niroula MR, Niyazov RA, Nozar M, Osipenko M, Ostrovidov AI, Park K, Pasyuk E, Paterson C, Pereira SA, Pierce J, Pivnyuk N, Pogorelko O, Pozdniakov S, Price JW, Procureur S, Prok Y, Raue BA, Ricco G, Ripani M, Ritchie BG, Ronchetti F, Rosner G, Rossi P, Sabatié F, Salamanca J, Salgado C, Santoro JP, Sapunenko V, Schumacher RA, Serov VS, Sharabian YG, Sharov D, Shvedunov NV, Smith LC, Sober DI, Sokhan D, Stavinsky A, Stepanyan SS, Stepanyan S, Stokes BE, Stoler P, Strauch S, Taiuti M, Tedeschi DJ, Tkabladze A, Tkachenko S, Tur C, Ungaro M, Vineyard MF, Vlassov AV, Watts DP, Weinstein LB, Weygand DP, Williams M, Wolin E, Wood MH, Yegneswaran A, Zana L, Zhang J, Zhao B, Zhao ZW. Bayesian analysis of pentaquark signals from CLAS data. PHYSICAL REVIEW LETTERS 2008; 100:052001. [PMID: 18352361 DOI: 10.1103/physrevlett.100.052001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/20/2007] [Indexed: 05/26/2023]
Abstract
We examine the results of two measurements by the CLAS collaboration, one of which claimed evidence for a Theta(+) pentaquark, while the other found no such evidence. The unique feature of these two experiments was that they were performed with the same experimental setup. Using a Bayesian analysis, we find that the results of the two experiments are in fact compatible with each other, but that the first measurement did not contain sufficient information to determine unambiguously the existence of a Theta(+). Further, we suggest a means by which the existence of a new candidate particle can be tested in a rigorous manner.
Collapse
|
115
|
Zittermann A, Schleithoff S, Gotting C, Fuchs U, Kuhn J, Wlost S, Kleesiek K, Tenderich G, Koerfer R. 176: Calcitriol Deficiency Is Associated with Increased Mortality Risk in Cardiac Transplant Recipients. J Heart Lung Transplant 2008. [DOI: 10.1016/j.healun.2007.11.183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
116
|
Nasseripour R, Wood MH, Djalali C, Weygand DP, Tur C, Mosel U, Muehlich P, Adams G, Amaryan MJ, Ambrozewicz P, Anghinolfi M, Asryan G, Avakian H, Bagdasaryan H, Baillie N, Ball JP, Baltzell NA, Barrow S, Battaglieri M, Bedlinskiy I, Bektasoglu M, Bellis M, Benmouna N, Berman BL, Biselli AS, Blaszczyk L, Bouchigny S, Boiarinov S, Bradford R, Branford D, Briscoe WJ, Brooks WK, Bültmann S, Burkert VD, Butuceanu C, Calarco JR, Careccia SL, Carman DS, Carnahan B, Casey L, Chen S, Cole PL, Collins P, Coltharp P, Crabb D, Crannell H, Crede V, Cummings JP, Dashyan N, De Masi R, De Vita R, De Sanctis E, Degtyarenko PV, Denizli H, Dennis L, Deur A, Dharmawardane KV, Dickson R, Dodge GE, Doughty D, Dugger M, Dytman S, Dzyubak OP, Egiyan H, Egiyan KS, El Fassi L, Elouadrhiri L, Eugenio P, Fedotov G, Feldman G, Feuerbach RJ, Funsten H, Garçon M, Gavalian G, Gilfoyle GP, Giovanetti KL, Girod FX, Goetz JT, Gordon CIO, Gothe RW, Griffioen KA, Guidal M, Guler N, Guo L, Gyurjyan V, Hadjidakis C, Hafidi K, Hakobyan H, Hakobyan RS, Hanretty C, Hardie J, Hersman FW, Hicks K, Hleiqawi I, Holtrop M, Hyde-Wright CE, Ilieva Y, Ireland DG, Ishkhanov BS, Isupov EL, Ito MM, Jenkins D, Jo HS, Johnstone JR, Joo K, Juengst HG, Kalantarians N, Kellie JD, Khandaker M, Kim W, Klein A, Klein FJ, Klimenko AV, Kossov M, Krahn Z, Kramer LH, Kubarovsky V, Kuhn J, Kuhn SE, Kuleshov SV, Lachniet J, Laget JM, Langheinrich J, Lawrence D, Li J, Livingston K, Lu HY, Maccormick M, Markov N, Mattione P, McAleer S, McKinnon B, McNabb JWC, Mecking BA, Mehrabyan S, Melone JJ, Mestayer MD, Meyer CA, Mibe T, Mikhailov K, Minehart R, Mirazita M, Miskimen R, Mokeev V, Moriya K, Morrow SA, Moteabbed M, Mueller J, Munevar E, Mutchler GS, Nadel-Turonski P, Niccolai S, Niculescu G, Niculescu I, Niczyporuk BB, Niroula MR, Niyazov RA, Nozar M, Osipenko M, Ostrovidov AI, Park K, Pasyuk E, Paterson C, Anefalos Pereira S, Pierce J, Pivnyuk N, Pocanic D, Pogorelko O, Pozdniakov S, Preedom BM, Price JW, Prok Y, Protopopescu D, Raue BA, Riccardi G, Ricco G, Ripani M, Ritchie BG, Ronchetti F, Rosner G, Rossi P, Sabatié F, Salamanca J, Salgado C, Santoro JP, Sapunenko V, Schumacher RA, Serov VS, Sharabian YG, Sharov D, Shvedunov NV, Smith ES, Smith LC, Sober DI, Sokhan D, Stavinsky A, Stepanyan SS, Stepanyan S, Stokes BE, Stoler P, Strakovsky II, Strauch S, Taiuti M, Tedeschi DJ, Tkabladze A, Tkachenko S, Todor L, Ungaro M, Vineyard MF, Vlassov AV, Watts DP, Weinstein LB, Williams M, Wolin E, Yegneswaran A, Zana L, Zhang B, Zhang J, Zhao B, Zhao ZW. Search for medium modifications of the rho meson. PHYSICAL REVIEW LETTERS 2007; 99:262302. [PMID: 18233570 DOI: 10.1103/physrevlett.99.262302] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/20/2007] [Indexed: 05/25/2023]
Abstract
The photoproduction of vector mesons on various nuclei has been studied using the CLAS detector at Jefferson Laboratory. The vector mesons, rho, omega, and varphi, are observed via their decay to e;{+}e;{-}, in order to reduce the effects of final-state interactions in the nucleus. Of particular interest are possible in-medium effects on the properties of the rho meson. The rho mass spectrum is extracted from the data on various nuclei, 2H, C, Fe, and Ti. We observe no significant mass shift and some broadening consistent with expected collisional broadening for the rho meson.
Collapse
|
117
|
Brophy DF, Martin EJ, Nolte ME, Kuhn JG, Carr ME. Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients. Haemophilia 2007; 13:533-41. [PMID: 17880440 DOI: 10.1111/j.1365-2516.2007.01524.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
NN1731 is a novel variant of recombinant factor VIIa (rFVIIa) that binds to activated platelets, but has greater enzymatic activity than rFVIIa in generating FXa and thrombin. The effect of NN1731 on clot structure and platelet function was characterized ex vivo in whole blood from healthy volunteers and haemophilic patients. Blood samples from six healthy volunteers, nine haemophilia A patients with and without inhibitors and one acquired haemophilia A patient, were spiked with increasing concentrations (0.32, 0.64 and 1.28 microg mL(-1)) of rFVIIa and NN1731. Platelet contractile force (PCF) or platelet function, clot elastic modulus (CEM) or clot structure, and force onset time (FOT) or the thrombin generation time (TGT) were determined using the Hemodyne Hemostasis Analysis System (HAS). Baseline PCF, CEM and FOT values in patients were abnormal compared to healthy volunteers' baseline values. Overall, haemophilia blood samples with or without inhibitors spiked with NN1731 had significantly greater PCF, CEM and shorter FOT values relative to samples spiked with corresponding doses of rFVIIa. The variability in response to treatment between patients was greater with rFVIIa compared to NN1731. At 1.28 microg mL(-1) (90 microg kg(-1)), NN1731 normalized PCF, CEM and FOT in nine of 10 patients, while rFVIIa normalized these parameters in four of 10 patients. Increasing in vitro concentrations of NN1731 normalized platelet function, clot structure and thrombin generation consistently in haemophilia blood with or without inhibitors. NN1731 may be a promising haemostatic agent for patients with bleeding disorders. These results should be confirmed in an in vivo study.
Collapse
|
118
|
Kuhn J. Die historische Entwicklung der kommunalen Gesundheitsberichterstattung - eine Forschungslücke. DAS GESUNDHEITSWESEN 2007; 69:507-13. [DOI: 10.1055/s-2007-992160] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
119
|
Armstrong DS, Arvieux J, Asaturyan R, Averett T, Bailey SL, Batigne G, Beck DH, Beise EJ, Benesch J, Bimbot L, Birchall J, Biselli A, Bosted P, Boukobza E, Breuer H, Carlini R, Carr R, Chant N, Chao YC, Chattopadhyay S, Clark R, Covrig S, Cowley A, Dale D, Davis C, Falk W, Finn JM, Forest T, Franklin G, Furget C, Gaskell D, Grames J, Griffioen KA, Grimm K, Guillon B, Guler H, Hannelius L, Hasty R, Allen AH, Horn T, Johnston K, Jones M, Kammel P, Kazimi R, King PM, Kolarkar A, Korkmaz E, Korsch W, Kox S, Kuhn J, Lachniet J, Lee L, Lenoble J, Liatard E, Liu J, Loupias B, Lung A, Marchand D, Martin JW, McFarlane KW, McKee DW, McKeown RD, Merchez F, Mkrtchyan H, Moffit B, Morlet M, Nakagawa I, Nakahara K, Neveling R, Ong S, Page S, Papavassiliou V, Pate SF, Phillips SK, Pitt ML, Poelker M, Porcelli TA, Quéméner G, Quinn B, Ramsay WD, Rauf AW, Real JS, Roche J, Roos P, Rutledge GA, Secrest J, Simicevic N, Smith GR, Spayde DT, Stepanyan S, Stutzman M, Sulkosky V, Tadevosyan V, Tieulent R, Van de Wiele J, van Oers WTH, Voutier E, Vulcan W, Warren G, Wells SP, Williamson SE, Wood SA, Yan C, Yun J, Zeps V. Transverse beam spin asymmetries in forward-angle elastic electron-proton scattering. PHYSICAL REVIEW LETTERS 2007; 99:092301. [PMID: 17930999 DOI: 10.1103/physrevlett.99.092301] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/11/2007] [Indexed: 05/25/2023]
Abstract
We have measured the beam-normal single-spin asymmetry in elastic scattering of transversely polarized 3 GeV electrons from unpolarized protons at Q2=0.15, 0.25 (GeV/c)2. The results are inconsistent with calculations solely using the elastic nucleon intermediate state and generally agree with calculations with significant inelastic hadronic intermediate state contributions. A(n) provides a direct probe of the imaginary component of the 2gamma exchange amplitude, the complete description of which is important in the interpretation of data from precision electron-scattering experiments.
Collapse
|
120
|
Kuhn J, Huff W, Lee SH, Lenartz D, Sturm V, Klosterkötter J. Tiefenhirnstimulation bei psychiatrischen Erkrankungen. FORTSCHRITTE DER NEUROLOGIE-PSYCHIATRIE 2007. [DOI: 10.1055/s-2006-955005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
121
|
Kuhn J, Bewermeyer H, Miyajima H, Takahashi Y, Kuhn KF, Hoogenraad TU. Treatment of symptomatic heterozygous aceruloplasminemia with oral zinc sulphate. Brain Dev 2007; 29:450-3. [PMID: 17307325 DOI: 10.1016/j.braindev.2007.01.001] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/05/2006] [Revised: 12/21/2006] [Accepted: 01/10/2007] [Indexed: 10/23/2022]
Abstract
Aceruloplasminemia is an autosomal recessive and phenotypically primarily neurodegenerative disease caused by a homozygous mutation of the ceruloplasmin gene. The absence of ceruloplasmin and its ferroxidase activity leads to pathological iron overload in the brain and other organs. While heterozygous carriers of ceruloplasmin gene mutations have been believed to be asymptomatic, a number of cases with neurological deficits have recently been described. To date, an effective treatment has not been established for either aceruloplasminemia or symptomatic heterozygous aceruloplasminemia. The present report concerns the beneficial treatment of an 18-year-old girl with extrapyramidal and cerebellar-mediated movement disorder caused by a heterozygous mutation of the ceruloplasmin gene using oral zinc sulphate.
Collapse
|
122
|
Egiyan KS, Asryan G, Gevorgyan N, Griffioen KA, Laget JM, Kuhn SE, Adams G, Amaryan MJ, Ambrozewicz P, Anghinolfi M, Audit G, Avakian H, Bagdasaryan H, Baillie N, Ball JP, Baltzell NA, Barrow S, Batourine V, Battaglieri M, Bedlinskiy I, Bektasoglu M, Bellis M, Benmouna N, Berman BL, Biselli AS, Blaszczyk L, Bouchigny S, Boiarinov S, Bradford R, Branford D, Briscoe WJ, Brooks WK, Bültmann S, Burkert VD, Butuceanu C, Calarco JR, Careccia SL, Carman DS, Cazes A, Chen S, Cole PL, Collins P, Coltharp P, Cords D, Corvisiero P, Crabb D, Crede V, Cummings JP, Dashyan N, De Masi R, De Vita R, De Sanctis E, Degtyarenko PV, Denizli H, Dennis L, Deur A, Dharmawardane KV, Dickson R, Djalali C, Dodge GE, Donnelly J, Doughty D, Dugger M, Dytman S, Dzyubak OP, Egiyan H, El Fassi L, Elouadrhiri L, Eugenio P, Fatemi R, Fedotov G, Feldman G, Feuerbach RJ, Fersch R, Garçon M, Gavalian G, Gilfoyle GP, Giovanetti KL, Girod FX, Goetz JT, Gonenc A, Gordon CIO, Gothe RW, Guidal M, Guillo M, Guler N, Guo L, Gyurjyan V, Hadjidakis C, Hafidi K, Hakobyan H, Hakobyan RS, Hanretty C, Hardie J, Hersman FW, Hicks K, Hleiqawi I, Holtrop M, Hyde-Wright CE, Ilieva Y, Ireland DG, Ishkhanov BS, Isupov EL, Ito MM, Jenkins D, Jo HS, Joo K, Juengst HG, Kalantarians N, Kellie JD, Khandaker M, Kim W, Klein A, Klein FJ, Klimenko AV, Kossov M, Krahn Z, Kramer LH, Kubarovsky V, Kuhn J, Kuleshov SV, Lachniet J, Langheinrich J, Lawrence D, Li J, Livingston K, Lu HY, Maccormick M, Marchand C, Markov N, Mattione P, McAleer S, McKinnon B, McNabb JWC, Mecking BA, Mehrabyan S, Melone JJ, Mestayer MD, Meyer CA, Mibe T, Mikhailov K, Minehart R, Mirazita M, Miskimen R, Mokeev V, Moriya K, Morrow SA, Moteabbed M, Mueller J, Munevar E, Mutchler GS, Nadel-Turonski P, Nasseripour R, Niccolai S, Niculescu G, Niculescu I, Niczyporuk BB, Niroula MR, Niyazov RA, Nozar M, O'Rielly GV, Osipenko M, Ostrovidov AI, Park K, Pasyuk E, Paterson C, Anefalos Pereira S, Pierce J, Pivnyuk N, Pocanic D, Pogorelko O, Pozdniakov S, Preedom BM, Price JW, Prok Y, Protopopescu D, Raue BA, Riccardi G, Ricco G, Ripani M, Ritchie BG, Ronchetti F, Rosner G, Rossi P, Sabatié F, Salamanca J, Salgado C, Santoro JP, Sapunenko V, Schumacher RA, Serov VS, Sharabian YG, Shvedunov NV, Skabelin AV, Smith ES, Smith LC, Sober DI, Sokhan D, Stavinsky A, Stepanyan SS, Stepanyan S, Stokes BE, Stoler P, Strauch S, Taiuti M, Tedeschi DJ, Thoma U, Tkabladze A, Tkachenko S, Todor L, Tur C, Ungaro M, Vineyard MF, Vlassov AV, Watts DP, Weinstein LB, Weygand DP, Williams M, Wolin E, Wood MH, Yegneswaran A, Zana L, Zhang J, Zhao B, Zhao ZW. Experimental study of exclusive 2H(e,e'p)n reaction mechanisms at high Q2. PHYSICAL REVIEW LETTERS 2007; 98:262502. [PMID: 17678084 DOI: 10.1103/physrevlett.98.262502] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/09/2007] [Indexed: 05/16/2023]
Abstract
The reaction 2H(e,e'p)n has been studied with full kinematic coverage for photon virtuality 1.75<Q2<5.5 GeV2. Comparisons of experimental data with theory indicate that for very low values of neutron recoil momentum (p(n)<100 MeV/c) the neutron is primarily a spectator and the reaction can be described by the plane-wave impulse approximation. For 100<p(n)<750 MeV/c, proton-neutron rescattering dominates the cross section, while Delta production followed by the NDelta-->NN transition is the primary contribution at higher momenta.
Collapse
|
123
|
Robins HI, Wen PY, Chang SM, Kuhn J, Lamborn K, Cloughesy T, Glibert MR, Yung WK, Dancey J, Prados MD. Phase I study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (MG) (NABTC 04–02). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.2057] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2057 Background: Glioblastomas (GBM) frequently have amplification/mutation of EGFR and inactivation of PTEN. Although single agent EGFR and mTOR inhibitors have only modest activity, there is a rationale for combinations of these agents. Methods: The North American Brain Tumor Consortium (NABTC) is conducting a phase I/II study of the EGFR inhibitor erlotinib in combination with the mTOR inhibitor CCI-779 in recurrent MG. Eligibility criteria were histologically proven GBM and anaplastic gliomas (AG), radiologic progression, > 18 yrs old, KPS > 60, adequate bone marrow reserve and organ function. Patients (pts) must not be receiving enzyme inducing antiepileptic drugs. The dose of erlotinib was fixed at 150 mg/d. Patients initially received CCI-779 50 mg intravenously once weekly and the dose was adjusted based on toxicities. Dose-limiting toxicities (DLT), determined during the first 4 weeks of therapy, were defined as any grade (G) 4 hematologic toxicity except for G3 thrombocytopenia, and any G3 or unacceptable G2 non-hematologic toxicities. Escalation was performed in groups of 3. The maximum tolerated dose (MTD) was defined as the dose at which DLTs occurred in no more than 1/6 pts. Results: To date 22 eligible pts have been enrolled (15 GBM; 7 AG). Patient characteristics were 12 male, 10 female; median age: 54 (26–74); median KPS 90 (70–100); median prior chemotherapy regimens 1 (0–3). Two of 3 pts receiving 50 mg of CCI-779 developed DLTs (intolerable G2 rash & mucositis, & G3 liver function abnormalities; G3 rash & dehydration). Three of 6 pts receiving 25 mg of CCI-779 weekly experienced DLTs (G3 rash; G3 rash, diarrhea, dehydration; G3 mucositis & infection). Two of 6 patients receiving weekly 15 mg of CCI-779 experienced G3 rash. The protocol was amended to define a DLT only if > G3 toxicities persisted despite maximal therapy. Six additional pts were treated at 15 mg of CCI-779. One of 6 pts developed a G3 rash. Conclusions: The combination of erlotinib and CCI-779 was associated with a higher than expected incidence of rash and mucositis. The MTD for this combination is likely to be 150 mg/d of erlotinib and 15 mg/d of CCI-779. Final pharmacokinetics and response data will be presented. No significant financial relationships to disclose.
Collapse
|
124
|
Wen PY, Puduvalli V, Kuhn J, Reid J, Cloughesy T, Yung WA, Chang SM, Robbins HI, McGovern R, Ames M, Prados MD. Phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with temozolomide (TMZ) in patients with malignant gliomas (NABTC 04–03). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.2039] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2039 Background: Vorinostat (V) is an oral inhibitor of histone deacetylase. In preclinical studies it inhibits growth of glioblastoma (GBM) cell lines and has supra-additive activity when combined with TMZ. Methods: The North American Brain Tumor Consortium (NABTC) is conducting a phase I study of V in combination with TMZ in patients with malignant gliomas (MG). Eligibility criteria are histologically proven GBM and anaplastic gliomas (AG) who have received radiotherapy and have not progressed on temozolomide, > 18 yrs old, life expectancy > 8 weeks, KPS > 60, adequate bone marrow reserve and organ function. There was no limitation to the type of antiepileptic drugs that could be used. All patients received TMZ at a dose of 150 mg/m2/day on days 1–5 days every 28 days. Variable doses of V were administered with food on days 1–14 every 28 days. Dose-limiting toxicities (DLT), determined during the first 4 weeks of therapy, were defined as any grade 4 hematologic toxicity except for grade 3 thrombocytopenia, and any grade 3 non-hematologic toxicities. Escalation was performed in standard groups of 3. The maximum tolerated dose (MTD) was defined as the dose at which DLTs occurred in no more than 1/6 patients. PKs were determined on cycle 1 for TMZ, V and its metabolites. Results: To date, 19 eligible patients have been enrolled (15 GBM; 4 AG). Patients’ characteristics are 11 male, 8 female; median age 54 yrs (36–78); median KPS 90 (70–100). DLTs were encountered at 300 mg bid of vorinostat (1 grade 3 thrombocytopenia; 1 grade 3 fatigue in 3 patients), 200 mg tid (1 grade 3 nausea, 1 grade 4 thrombocytopenia in 3 patients) and 200 mg twice daily (grade 3 fatigue in 2/6 patients). No DLTs were encountered in 6 patients receiving 300 mg daily. TMZ PKs included [n=16: Cmax 5.2 (± 1.55) μg/ml; AUC 20.1 (±4.66) μg x hr/ml; t1/2 1.9 (±0.32)/hr]. Vorinostat PKs (300mg dose level) were [n=4; Cmax 267 (±174) ng/ml; AUC0–8 603 (±197) ng x hr/ml]. The t1/2 for V and its glucuronide metabolite were identical (1.6 hrs) vs. 5.6 hrs for the acid metabolite. Conclusions: The MTD of vorinostat in combination with TMZ is 300 mg daily on days 1–14 every 28 days. Final PK results, and toxicities from an additional 10 patients enrolled at the MTD will be presented. [Table: see text]
Collapse
|
125
|
Nemunaitis J, Senzer N, Khalil I, Shen Y, Kumar P, Tong A, Kuhn J, Lamont J, Nemunaitis M, Rao D, Zhang YA, Zhou Y, Vorhies J, Maples P, Hill C, Shanahan D. Proof concept for clinical justification of network mapping for personalized cancer therapeutics. Cancer Gene Ther 2007; 14:686-95. [PMID: 17541424 DOI: 10.1038/sj.cgt.7701057] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
To identify signature targets associated with patient-specific cancer lesions based on tumor versus normal tissue differential protein and mRNA coexpression patterns for the purpose of synthesizing cancer-specific customized RNA interference knockdown therapeutics. Analysis of biopsied tissue involved two-dimensional difference in-gel electrophoresis (2D-DIGE) analysis coupled with MALDI-TOF/TOF mass spectrometry for proteomic assessment. Standard microarray techniques were utilized for mRNA analysis. Priority was assigned to overexpressed protein targets with co-overexpressed genes with a high likelihood of functional nodal centrality in the cancer network as defined by the interactive databases BIND, HPRD and ResNet. HPLC-grade small interfering RNA (siRNA) duplexes were utilized to assess knockdown of target proteins in expressive cell lines as measured by western blot. Seven patients with metastatic cancer underwent biopsy. One patient (RW001) had biopsies from two disease sites 10 months apart. Seven priority proteins were identified, one for each patient (RACK 1, Ras related nuclear protein, heat-shock 27 kDa protein 1, superoxide dismutase, enolase1, stathmin1 and cofilin1). Prioritized proteins in RW001 from the two disease sites over time were the same. We demonstrated >80% siRNA inhibition of RACK 1 and stathmin1 of inexpressive malignant cell lines with correlated cell kill. Identification of functionally relevant target gene fingerprints, unique to an individual's cancer, is feasible 'at the bedside' and can be utilized to synthesize siRNA knockdown therapeutics. Further animal safety testing followed by clinical study is recommended.
Collapse
|